臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 52805551 在线人数 : 595 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"shih j y"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 221-230 / 1137 (共114頁)
<< < 18 19 20 21 22 23 24 25 26 27 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-09-17T03:21:17Z	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations	SHENG-KAI LIANG; Ko J.-C.; Yang J.C.-H.; Shih J.-Y.
臺大學術典藏	2021-09-17T03:21:16Z	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort	SHENG-KAI LIANG; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-09-17T02:51:01Z	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma	Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y.
臺大學術典藏	2021-09-17T02:50:57Z	Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study	Liang S.-K.; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y.
臺大學術典藏	2021-09-17T02:50:52Z	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort	Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-09-17T02:50:51Z	Establishing aspergillus-specific igg cut-off level for chronic pulmonary aspergillosis diagnosis: Multicenter prospective cohort study	MENG-RUI LEE; Huang H.-L.; Keng L.-T.; Chang H.-L.; Sheu C.-C.; Fu P.-K.; Wang J.-Y.; Chong I.-W.; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-09-15T01:20:52Z	IGFBP7 Drives resistance to epidermal growth factor receptor tyrosine kinase inhibition in lung cancer	Wu S.-G.; Chang T.-H.; Tsai M.-F.; Liu Y.-N.; CHIA-LANG HSU; Chang Y.-L.; Yu C.-J.; Shih J.-Y.
臺大學術典藏	2021-09-15T01:20:50Z	MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process	Wang H.-Y.; Liu Y.-N.; Wu S.-G.; CHIA-LANG HSU; Chang T.-H.; Tsai M.-F.; Lin Y.-T.; Shih J.-Y.
臺大學術典藏	2021-09-15T01:20:46Z	Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1	Chung K.-P.; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; CHIA-LANG HSU; Nakahira K.; Huang Y.-T.; Lin M.-W.; Wu S.-G.; Shih J.-Y.; Chang Y.-L.; Yu C.-J.
臺大學術典藏	2021-09-09T05:25:29Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.

顯示項目 221-230 / 1137 (共114頁)
<< < 18 19 20 21 22 23 24 25 26 27 > >>
每頁顯示[10|25|50]項目